Compare NTST & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | XNCR |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2020 | 2013 |
| Metric | NTST | XNCR |
|---|---|---|
| Price | $17.39 | $24.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 14 |
| Target Price | $22.92 | ★ $31.42 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.09% | N/A |
| EPS Growth | ★ 150.00 | 65.36 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $195,006,000.00 | $125,576,000.00 |
| Revenue This Year | $29.01 | $14.05 |
| Revenue Next Year | $18.49 | N/A |
| P/E Ratio | $149.63 | ★ N/A |
| Revenue Growth | ★ 19.79 | 13.65 |
| 52 Week Low | $17.02 | $10.38 |
| 52 Week High | $22.47 | $30.61 |
| Indicator | NTST | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 18.87 | 51.52 |
| Support Level | $17.10 | $23.36 |
| Resistance Level | $17.88 | $30.61 |
| Average True Range (ATR) | 0.43 | 1.03 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 0.80 | 55.23 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.